Quality Evaluation of Metabolic-Associated Fatty Liver Disease Guidelines and Expert Consensus

Abstract

The purpose of this study is to evaluate and analyze the quality of guidelines and expert consensus on clinical practice regarding metabolically associated fatty liver disease (MAFLD) over the past five years. Data from the websites were retrieved using computers. We evaluated guidelines and expert consensus on MAFLD that were officially published between January 1, 2018 and March 24, 2023. Two evaluators independently examined the literature and extracted data. The included literature on guidelines and expert consensus was then subjected to quality review and analysis using assessment tools from Appraisal of Guidelines for Research and Evaluation (AGREE) II and the Joanna Briggs Institute Qualitative Assessment and Review Instrument (JBI-QARI) (2016). The intraclass correlation coefficient (ICC) values of all items on the AGREE II scale for the two evaluators were greater than 0.75, indicating a high degree of agreement between their assessments. Scope and purpose (48.90%), participants (49.21%), rigor in the formulation process (56.97%), clarity of expression (90.08%), applicability (66.08%), and independence of file compiling (60.12%) were the AGREE II scoring items with the standardized average scores. Apart from the participants, the average scores of all the scoring items in the guidelines from other countries other than China were higher than those from China (|Z|+>+2.272, p+<+0.05). MAFLD guidelines must be revised to enhance their methodological quality. When creating guidelines, it is recommended that the formulators strictly adhere to the formulation and drafting standards of AGREE II and elevate the quality of the guidelines.

Key words

expert consensus - guidelines - metabolically associated fatty liver disease (MAFLD) - non-alcoholic fatty liver disease (NAFLD) - quality evaluation

Publikationsverlauf

Eingereicht: 23. August 2023

Angenommen nach Revision: 01. Dezember 2023

Artikel online veröffentlicht:
29. Januar 2024

• References

• 1 Eslam M, Sanyal AJ, George J. et al. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020; 158: 1999-2014
• 2 Younossi ZM, Golabi P, Paik JM. et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023; 77: 1335-1347
• 3 Lazarus JV, Mark HE, Villota-Rivas M. et al. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. J Hepatol 2022; 76: 771-780
• 4 Fen Z, Yufang H, Xue C. et al. Guide research and evaluation tool AGREE II and supplementary explanations and reflections on scores in various fields. J Nurs 2018; 25: 56-58
• 5 Brouwers MC, Kho ME, Browman GP. et al. AGREE II: advancing guideline development, reporting, and evaluation in health care. Prev Med 2010; 51: 421-425
• 6 Ying G, Huiwen Z, Yingfeng Z. et al. JBI evidence-based health center’s quality assessment tool for different types of research – The quality evaluation of diagnostic and economic evaluation. J Adv Nurs Ed. 2018. 33. 701-703
• 7 Lili W, Haoran L, Zijun W. et al. Clinical Practice Guidelines of Rehabilitation: Methodological Quality. Chin J Rehabil Theory Pract 2020; 26: 144-149
• 8 Cusi K, Isaacs S, Barb D. et al. American association of clinical endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty Liver disease in primary care and endocrinology clinical settings: co-sponsored by the American association for the study of liver diseases (AASLD). Endocr Pract 2022; 28: 528-562
• 9 Aller R, Fernández-Rodríguez C, Lo Iacono O. et al. Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline. Gastroenterol Hepatol 2018; 41: 328-349
• 10 Kang SH, Lee HW, Yoo JJ. et al. KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease. Clin Mol Hepatol 2021; 27: 363-401
• 11 Eslam M, Sarin SK, Wong VW. et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 2020; 14: 889-919
• 12 Associazione Italiana per lo Studio del Fegato (AISF) et al. Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO). Eat Weight Disord 2022; 27: 1603-1619
• 13 Fouad Y, Esmat G, Elwakil R. et al. The egyptian clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Saudi J Gastroenterol 2022; 28: 3-20
• 14 National Workshop on Fatty Liver and Alcoholic Liver Disease et al. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update. J Clin Hepatol 2018; 34: 947-957
• 15 Rinella ME, Neuschwander-Tetri BA, Siddiqui MS. et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology 2023; 77: 1797-1835
• 16 Chan WK, Tan SS, Chan SP. et al. Malaysian society of gastroenterology and hepatology consensus statement on metabolic dysfunction-associated fatty liver disease. J Gastroenterol Hepatol 2022; 37: 795-811
• 17 Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R. et al. The Mexican consensus on nonalcoholic fatty liver disease. Rev Gastroenterol Mex (Engl Ed) 2019; 84: 69-99
• 18 Alswat KA, Fallatah HI, Al-Judaibi B. et al. Position statement on the diagnosis and management of non-alcoholic fatty liver disease. Saudi Med J 2019; 40: 531-540
• 19 Lazarus JV, Mark HE, Anstee QM. et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol 2022; 19: 60-78
• 20 Chinese Society of Endocrinology. Consensus for diagnosis and treatment of nonalcoholic fatty liver diseases and metabolic disorders (2nd Edition). J Clin Hepatol 2018; 34: 2103-2108
• 21 Kamada Y, Takahashi H, Shimizu M. et al. Clinical practice advice on lifestyle modification in the management of nonalcoholic fatty liver disease in Japan: an expert review. J Gastroenterol 2021; 56: 1045-1061
• 22 George ES, Forsyth A, Itsiopoulos C. et al. Practical dietary recommendations for the prevention and management of nonalcoholic fatty liver disease in adults. Adv Nutr 2018; 9: 30-40
• 23 Ratziu V, Ghabril M, Romero-Gomez M. et al. Recommendations for management and treatment of nonalcoholic steatohepatitis. Transplantation 2019; 103: 28-38
• 24 Younossi ZM, Corey KE, Lim JK. AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: Expert review. Gastroenterology 2021; 160: 912-918